Reduced-dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study
- 23 April 2020
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 135 (17), 1458-1466
- https://doi.org/10.1182/blood.2019004215
Abstract
Treatment-related mortality is common among children with acute lymphoblastic leukemia (ALL) treated in poor-resource settings. We applied a simplified flow cytometric assay to identify patients with precursor B-cell ALL (B-ALL) at very low risk (VLR) of relapse and treated them with a reduced-intensity treatment plan (RELLA05). VLR criteria include favorable presenting features (age >= 1 and < 10 years), white blood cell count of <50 x 10(9)/L, lack of extramedullary leukemia, and minimal residual disease level of <0.01% on remission induction day 19. Except for 2 doses of daunorubicin, treatment of patients with VLR B-ALL consisted of a combination of agents with relatively low myelotoxicity profiles, including corticosteroids, vincristine, L-asparaginase, methotrexate, and 6-mercaptopurine. Cyclo-phosphamide, systemic cytarabine, and central nervous system radiotherapywere not used. Of 454 patients with ALL treated at the Instituto de Medicina Integral Professor Fernando Figueira in Recife, Brazil, between December 2005 and June 2015, 101 were classified as having VLR B-ALL. There were no cases of death resulting from toxicity or treatment abandonment during remission induction. At a median follow-up of 6.6 years, there were 8 major adverse events: 6 relapses, 1 treatment-related death (from septicemia) during remission, and 1 secondary myeloid leukemia. The estimated 5-year event-free and overall survival rates were 92.0% +/- 3.9% and 96.0% +/- 2.8%, respectively. The 5-year cumulative risk of relapse was 4.24% +/- 2.0%. The treatment was well tolerated. Episodes of neutropenia were of short duration. Patients with B-ALL selected by a combination of presenting features and degree of early response can be successfully treated with a mildly myelo-suppressive chemotherapy regimen.This publication has 36 references indexed in Scilit:
- Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemiaNature Genetics, 2011
- Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemiaBlood, 2010
- Benefits of the Intermittent Use of 6-Mercaptopurine and Methotrexate in Maintenance Treatment for Low-Risk Acute Lymphoblastic Leukemia in Children: Randomized Trial From the Brazilian Childhood Cooperative Group—Protocol ALL-99Journal of Clinical Oncology, 2010
- Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemiaLeukemia, 2009
- Treating Childhood Acute Lymphoblastic Leukemia without Cranial IrradiationThe New England Journal of Medicine, 2009
- High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemiaBlood, 2008
- A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcomeBlood, 2006
- Saving the Children — Improving Childhood Cancer Treatment in Developing CountriesThe New England Journal of Medicine, 2005
- Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research HospitalBlood, 2004
- A Reappraisal of the Results of Stopping Therapy in Childhood LeukemiaThe New England Journal of Medicine, 1979